The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research...
International Association for the Study of Lung Cancer Sep 11 2024 The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor wildtype , locally advanced/metastatic nonsquamous non-small cell lung cancer , according to research presented today at the International Association for the Study of Lung Cancer 's 2024 World Conference on...
Dr. Hidehito Horinouchi, of the National Cancer Center Hospital in Japan, participated in the LUMINOSITY phase 2 clinical trial aiming to identify the c-Met protein-overexpressing NSCLC population best suited to Teliso-V monotherapy and expand selected groups for further evaluation. In total, 172 patients with c-Met protein-OE EGFR WT nonsquamous NSCLC received at least one dose of Teliso-V, 57 of whom were Asian. A total of 48 Asian patients were evaluable for efficacy.
Angiogenesis Antibody Antibody-Drug Conjugate Cancer Cell Cell Proliferation Clinical Trial Efficacy Growth Factor Hospital Kinase Lung Cancer Non-Small Cell Lung Cancer Proliferation Receptor Research Small Cell Lung Cancer Tyrosine
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLCThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research...
Read more »
Zongertinib shows promising efficacy in HER2 mutation-positive NSCLCThe HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung...
Read more »
Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutationsThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS antitumor activity, according to research presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung...
Read more »
Results from study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLCA Phase III study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and immunotherapy (in combination or sequential), whose tumors highly expressed CEACAM5, was presented at the International Association for the Study of Lung...
Read more »
Immunotherapy before and after surgery benefits NSCLC patientsPeople with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
Read more »
Perioperative nivolumab may bolster survival over only neoadjuvant nivolumab plus chemotherapy for resectable NSCLCNew data from landmark analysis presented today reports a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy.
Read more »